Skip to search formSkip to main contentSkip to account menu

Tracleer

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2013
Highly Cited
2013
Bosentan (Tracleer) is an endothelin receptor antagonist prescribed for the treatment of pulmonary arterial hypertension (PAH… 
2013
2013
AIM To evaluate the efficiency and safety of long-term (12-month) treatment with the endothelin receptor antagonist bosentan… 
2012
2012
Review
2009
Review
2009
Bosentan (Tracleer) is an orally administered dual endothelin-1 (ET-1) receptor antagonist approved in the EU for reducing the… 
Review
2009
Review
2009
Bosentan (Tracleer) is an orally administered dual endothelin-1 (ET-1) receptor antagonist approved for use in patients with WHO… 
Highly Cited
2007
Highly Cited
2007
The elimination process of the endothelin receptor antagonist bosentan (Tracleer) in humans is entirely dependent on metabolism… 
2007
2007
When Merck KGaA purchased Geneva-based Serono in September, Actelion became Switzerland's largest biotech. 
2006
2006
  • J. Ransom
  • Nature Biotechnology
  • 2006
  • Corpus ID: 28513596
The best-performing stock from 2005 was a prime example of how biotech stocks are not as capricious as they may seem. 
2006
2006
S A N D I E G O — A second randomized clinical trial has confirmed that treatment with bosentan can help prevent the formation of… 
2003
2003
  • Drug and therapeutics bulletin
  • 2003
  • Corpus ID: 38335064
Pulmonary arterial hypertension is an uncommon but disabling and often fatal condition, in which there is a sustained rise in…